# Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas

> **NCT04197492** · PHASE2 · UNKNOWN · sponsor: **Huashan Hospital** · enrollment: 22 (estimated)

## Conditions studied

- Malignant Glioma

## Interventions

- **RADIATION:** Hypofractionated Stereotactic Radiotherapy
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT04197492
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-16
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04197492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04197492, "Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04197492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*